Catalyst Wire Dossier Catalyst Wire Dossier

NDV-01 (gemcitabine-docetaxel sustained-release)

gemcitabine/docetaxel sustained-release · Relmada Therapeutics, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NDV-01 (gemcitabine-docetaxel sustained-release), covering 2026-03-17 to 2026-03-17. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT [Phase 3]

See pricing